macs depletion column Search Results


macs depletion column  (Miltenyi Biotec)
96
Miltenyi Biotec macs depletion column
Macs Depletion Column, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/CD3+MicroBeads%2C+human+-+lyophilized/bio_rxiv__64898__2026__04__13__715606-268-14-18
Average 96 stars, based on 1 article reviews
macs depletion column - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
magnetic separation  (Miltenyi Biotec)
97
Miltenyi Biotec magnetic separation
Magnetic Separation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/MS+Columns/pmc08860096-201-6-15
Average 97 stars, based on 1 article reviews
magnetic separation - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
direct lineage cell depletion kit  (Miltenyi Biotec)
96
Miltenyi Biotec direct lineage cell depletion kit
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Direct Lineage Cell Depletion Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/Direct+Lineage+Cell+Depletion+Kit%2C+mouse/pmc08679673-63-12-21
Average 96 stars, based on 1 article reviews
direct lineage cell depletion kit - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
macs ls columns  (Miltenyi Biotec)
99
Miltenyi Biotec macs ls columns
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Macs Ls Columns, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/LS+Columns/pm37399024-285-20-23
Average 99 stars, based on 1 article reviews
macs ls columns - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
gene exp hhex mm00433954 m1  (Thermo Fisher)
85
Thermo Fisher gene exp hhex mm00433954 m1
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Gene Exp Hhex Mm00433954 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/Gene+Exp%2E+Hhex%2C+Mm00433954_m1/pmc04923324__mt201655x1-16-74-75
Average 85 stars, based on 1 article reviews
gene exp hhex mm00433954 m1 - by Bioz Stars, 2026-10
85/100 stars
  Buy from Supplier
macs cell separation ld columns  (Miltenyi Biotec)
96
Miltenyi Biotec macs cell separation ld columns
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Macs Cell Separation Ld Columns, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/LD+Columns/pmc09197253-36-20-25
Average 96 stars, based on 1 article reviews
macs cell separation ld columns - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
streptavidin microbead magnetic column depletion  (Miltenyi Biotec)
96
Miltenyi Biotec streptavidin microbead magnetic column depletion
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Streptavidin Microbead Magnetic Column Depletion, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/Streptavidin/pmc03460819-74-24-30
Average 96 stars, based on 1 article reviews
streptavidin microbead magnetic column depletion - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
magnetic bead separator  (Miltenyi Biotec)
96
Miltenyi Biotec magnetic bead separator
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Magnetic Bead Separator, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/MidiMACS+Separator/10__1161_slash_01__res__0000246095__90247__d4-49-26-34
Average 96 stars, based on 1 article reviews
magnetic bead separator - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
macs columns  (Becton Dickinson)
90
Becton Dickinson macs columns
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Macs Columns, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/macs+column/pmc03026719-442-15-47
Average 90 stars, based on 1 article reviews
macs columns - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
macs miltenyi biotec column  (Miltenyi Biotec)
96
Miltenyi Biotec macs miltenyi biotec column
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Macs Miltenyi Biotec Column, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/Lineage+Cell+Depletion+Kit%2C+mouse/pm35319286-95-6-7
Average 96 stars, based on 1 article reviews
macs miltenyi biotec column - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
ls macs column  (Miltenyi Biotec)
96
Miltenyi Biotec ls macs column
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Ls Macs Column, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/QuadroMACS+Separator/pm39615283-115-17-20
Average 96 stars, based on 1 article reviews
ls macs column - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
macs column  (Miltenyi Biotec)
96
Miltenyi Biotec macs column
Anti-CD117 mAb (ACK2) combined with AZA enhances HSC <t>depletion</t> and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute <t>cell</t> counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from <t>Lin–Sca1+c-Kit+)</t> in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.
Macs Column, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/macs+depletion+column/CD4+MicroBeads%2C+human/10__1111_slash_sji__13226-61-13-15
Average 96 stars, based on 1 article reviews
macs column - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Anti-CD117 mAb (ACK2) combined with AZA enhances HSC depletion and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute cell counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from Lin–Sca1+c-Kit+) in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.

Journal: Blood Advances

Article Title: 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice

doi: 10.1182/bloodadvances.2020003841

Figure Lengend Snippet: Anti-CD117 mAb (ACK2) combined with AZA enhances HSC depletion and delays HSC recovery in vivo. (A) Treatment schema for panels B-F. C57BL/6 mice were injected intravenously with a single dose of ACK2 or 2B8 at 500 µg 5 days before the start of treatment with AZA. AZA was administered intraperitoneally at 5 mg/kg once per day for 5 days. Mice were euthanized at 6, 10, or 20 days after the first dose of AZA; spleens and BM from both legs and spine were harvested and analyzed by flow cytometry for HSC depletion and depletion of mature myeloid and lymphoid cells. (B) Hematoxylin and eosin staining of a BM section of 1 femur at day 6 from a mouse treated with ACK2 only, AZA only, or ACK2-AZA. (C) Absolute cell counts of the different HSPC compartments in the BM of untreated controls and ACK2-AZA–treated mice on days 6, 10, and 20 after the start of AZA treatment as measured by flow cytometry. (D) Comparison of the absolute cell counts of different HSPC compartments in the BM of mice treated with AZA only or ACK2-AZA at baseline and at 6, 10, and 20 days after start of AZA. (E) Comparison of the absolute cell counts of LT-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. (F) Comparison of the absolute cell counts of ST-HSCs in the BM of mice treated with 2B8-AZA vs ACK2-AZA at baseline and on days 10 and 20 after the start of AZA treatment. For panels C-F, data for each experimental group were pooled from 2 independent experiments; n = 8-9 mice per group per time point. (G) Treatment schema for panels H-I. C57BL/6 mice were injected intravenously with a single dose of ACK2 500 µg 5 days before the start of treatment with AZA (administered intraperitoneally at a dose of 2.5 mg/kg per day for 3 days). Mice were euthanized 4 days after the first dose of AZA, and BM from both legs was harvested and analyzed by flow cytometry for annexin V and propidium iodide (PI) staining. (H) Representative flow cytometry plots of annexin V and PI staining (gated from Lin–Sca1+c-Kit+) in untreated controls and mice treated with ACK2, AZA 2.5 mg/kg, or ACK2-AZA. (I) Top: annexin V+; bottom: annexin V+/PI+; stained cells are shown as a percentage of LSK cells in the different treatment groups compared with untreated controls (n = 3-5 mice). Data are expressed as mean ± SD. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.

Article Snippet: For HSC transplantation, lineage depletion was performed with magnetic column separation and direct lineage cell depletion kit (MACS Separation Columns LS; Miltenyi Biotec) per the manufacturer’s instructions.

Techniques: In Vivo, Injection, Flow Cytometry, Staining, Comparison